APO RESEARCH · REPORT
Capecitabine
Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, which is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
Product & engineering
Understand the product.
Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, which is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
Common side effects include abdominal pain, vomiting, diarrhea, weakness, and rashes. Other severe side effects include blood clotting problems, allergic reactions, heart problems, and low blood cell counts. It is not recommended in people with kidney problems. Use during pregnancy may result in harm to the baby. Capecitabine, inside the body, is converted to 5-fluorouracil (5-FU) through which it acts. It belongs to the class of medications known as fluoropyrimidines, which also includes 5-fluorouracil and tegafur.
Selected research
Industry Research
Capecitabine Industry Research Report 2026
Market perspective
Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, which is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
Common side effects include abdominal pain, vomiting, diarrhea, weakness, and rashes. Other severe side effects include blood clotting problems, allergic reactions, heart problems, and low blood cell counts. It is not recommended in people with kidney problems. Use during pregnancy may result in harm to the baby. Capecitabine, inside the body, is converted to 5-fluorouracil (5-FU) through which it acts. It belongs to the class of medications known as fluoropyrimidines, which also includes 5-fluorouracil and tegafur.
Roche, Teva and Mylan are the top 3 of Capecitabine, with about 87% market shares.
Read the full market overview
Report Scope
This report quantifies the global Capecitabine market in terms of revenue (US$ million) and, where applicable, sales volume (Kg), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/Kg) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Capecitabine Market by Company
Roche
Teva
Mylan
Hikma
Hengrui Medicine
Cipla
Reliance Group
Hetero
Capecitabine Segment by Type
500 mg
150 mg
Capecitabine Segment by Application
Breast Cancer
Colorectal Cancer
Stomach Cancer
Capecitabine Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Capecitabine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Capecitabine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Capecitabine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Capecitabine manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Capecitabine by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Capecitabine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- 500 mg
- 150 mg
Applications
- Breast Cancer
- Colorectal Cancer
- Stomach Cancer
Companies covered
- Roche
- Teva
- Mylan
- Hikma
- Hengrui Medicine
- Cipla
- Reliance Group
- Hetero
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Capecitabine Market Size (2021-2032)
- 2.2.2 Global Capecitabine Sales (2021-2032)
- 2.2.3 Global Capecitabine Market Average Price (2021-2032)
- 2.3 Capecitabine by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 500 mg
- 2.3.3 150 mg
- 2.4 Capecitabine by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Breast Cancer
- 2.4.3 Colorectal Cancer
- 2.4.4 Stomach Cancer
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Capecitabine Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Capecitabine Sales (Kg) of Manufacturers (2021-2026)
- 3.3 Global Capecitabine Revenue of Manufacturers (2021-2026)
- 3.4 Global Capecitabine Average Price by Manufacturers (2021-2026)
- 3.5 Global Capecitabine Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Capecitabine, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Capecitabine, Product Type & Application
- 3.8 Global Manufacturers of Capecitabine, Established Date
- 3.9 Global Capecitabine Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Roche
- 4.1.1 Roche Company Information
- 4.1.2 Roche Business Overview
- 4.1.3 Roche Capecitabine Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Roche Capecitabine Product Portfolio
- 4.1.5 Roche Recent Developments
- 4.2 Teva
- 4.2.1 Teva Company Information
- 4.2.2 Teva Business Overview
- 4.2.3 Teva Capecitabine Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Teva Capecitabine Product Portfolio
- 4.2.5 Teva Recent Developments
- 4.3 Mylan
- 4.3.1 Mylan Company Information
- 4.3.2 Mylan Business Overview
- 4.3.3 Mylan Capecitabine Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Mylan Capecitabine Product Portfolio
- 4.3.5 Mylan Recent Developments
- 4.4 Hikma
- 4.4.1 Hikma Company Information
- 4.4.2 Hikma Business Overview
- 4.4.3 Hikma Capecitabine Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Hikma Capecitabine Product Portfolio
- 4.4.5 Hikma Recent Developments
- 4.5 Hengrui Medicine
- 4.5.1 Hengrui Medicine Company Information
- 4.5.2 Hengrui Medicine Business Overview
- 4.5.3 Hengrui Medicine Capecitabine Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Hengrui Medicine Capecitabine Product Portfolio
- 4.5.5 Hengrui Medicine Recent Developments
- 4.6 Cipla
- 4.6.1 Cipla Company Information
- 4.6.2 Cipla Business Overview
- 4.6.3 Cipla Capecitabine Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Cipla Capecitabine Product Portfolio
- 4.6.5 Cipla Recent Developments
- 4.7 Reliance Group
- 4.7.1 Reliance Group Company Information
- 4.7.2 Reliance Group Business Overview
- 4.7.3 Reliance Group Capecitabine Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Reliance Group Capecitabine Product Portfolio
- 4.7.5 Reliance Group Recent Developments
- 4.8 Hetero
- 4.8.1 Hetero Company Information
- 4.8.2 Hetero Business Overview
- 4.8.3 Hetero Capecitabine Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Hetero Capecitabine Product Portfolio
- 4.8.5 Hetero Recent Developments
5 Global Capecitabine Market Scenario by Region
- 5.1 Global Capecitabine Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Capecitabine Sales by Region: 2021-2032
- 5.2.1 Global Capecitabine Sales by Region: 2021-2026
- 5.2.2 Global Capecitabine Sales by Region: 2027-2032
- 5.3 Global Capecitabine Revenue by Region: 2021-2032
- 5.3.1 Global Capecitabine Revenue by Region: 2021-2026
- 5.3.2 Global Capecitabine Revenue by Region: 2027-2032
- 5.4 North America Capecitabine Market Facts & Figures by Country
- 5.4.1 North America Capecitabine Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Capecitabine Sales by Country (2021-2032)
- 5.4.3 North America Capecitabine Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Capecitabine Market Facts & Figures by Country
- 5.5.1 Europe Capecitabine Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Capecitabine Sales by Country (2021-2032)
- 5.5.3 Europe Capecitabine Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Capecitabine Market Facts & Figures by Country
- 5.6.1 Asia Pacific Capecitabine Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Capecitabine Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Capecitabine Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Capecitabine Market Facts & Figures by Country
- 5.7.1 South America Capecitabine Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Capecitabine Sales by Country (2021-2032)
- 5.7.3 South America Capecitabine Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Capecitabine Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Capecitabine Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Capecitabine Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Capecitabine Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Capecitabine Sales by Type (2021-2032)
- 6.1.1 Global Capecitabine Sales by Type (2021-2032) & (Kg)
- 6.1.2 Global Capecitabine Sales Market Share by Type (2021-2032)
- 6.2 Global Capecitabine Revenue by Type (2021-2032)
- 6.2.1 Global Capecitabine Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Capecitabine Revenue Market Share by Type (2021-2032)
- 6.3 Global Capecitabine Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Capecitabine Sales by Application (2021-2032)
- 7.1.1 Global Capecitabine Sales by Application (2021-2032) & (Kg)
- 7.1.2 Global Capecitabine Sales Market Share by Application (2021-2032)
- 7.2 Global Capecitabine Revenue by Application (2021-2032)
- 7.2.1 Global Capecitabine Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Capecitabine Revenue Market Share by Application (2021-2032)
- 7.3 Global Capecitabine Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Capecitabine Value Chain Analysis
- 8.1.1 Capecitabine Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Capecitabine Production Mode & Process
- 8.2 Capecitabine Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Capecitabine Distributors
- 8.2.3 Capecitabine Customers
9 Global Capecitabine Analyzing Market Dynamics
- 9.1 Capecitabine Industry Trends
- 9.2 Capecitabine Industry Drivers
- 9.3 Capecitabine Industry Opportunities and Challenges
- 9.4 Capecitabine Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst